Neonatal myocardial infarction: substantial improvement of cardiac function after autologous bone marrow-derived cell therapy

Zschirnt, Martin; Jux, Christian; Boenig, Halvard; Zeiher, Andreas M.; Aßmus, Birgit; Khalil, Markus; Kriebel, Thomas; Rupp, Stefan

doi:10.1007/s00392-019-01478-y

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cause of myocardial infarction in most paediatric patients is still unclear and the mortality rate is still high; neonatal myocardial infarction is a rare disease compared with adults. However, the treatment options in this case are limited 2,3 . In myocardial ischaemia and hypoxia of the newborn, the body has a decompensation reaction that could lead to hypoxic‐ischaemic injury to multiple organs, especially to the brain and heart.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Diosmetin exerts cardioprotective effect on myocardial ischaemia injury in neonatal rats by decreasing oxidative stress and myocardial apoptosis

Zhang³

et al. 2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Myocardial injury caused by the myocardial ischaemia (MI) is still a troublesome condition in the clinic, including apoptosis, oxidative stress and inflammation. Diosmetin inhibits the cellular apoptosis and inflammatory response and enhances antioxidant activity. So, this study was designed to investigate the cardioprotective effects of diosmetin on MI model neonatal rats. Forty Sprague Dawley (SD) rats 7 days old were randomly divided into five groups. Four groups of rats received diosmetin (50, 100, and 200 mg/kg) or vehicle (MI group) after ischaemia. Another group received vehicle without ischaemia to serve as a control group. Rats were pretreated with diosmetin intraperitoneally for 7 days and intoxicated with isoproterenol (ISO, 85 mg/kg, sc) on the last 2 days. The expression of apoptotic molecules, myocardial systolic function index, antioxidant enzymes and myocardial enzyme was analyzed. Compared with the control group, the proliferation marker proteins of Ki67 were increased significantly (P < .05), the MI group significantly increased the cardiac apoptosis, oxidative stress and myocardial enzymes, and weakened myocardial contractility. The levels of p‐P65/P65 were increased significantly (P < .05) with decreased p‐AKT/AKT and p‐Nrf2/Nrf2 (P < .05). Nevertheless, pretreatment with diosmetin reversed these changes, especially high‐dose group. In summary, diosmetin has significant potential as a therapeutic intervention to ameliorate myocardial injury after MI and provides the rationale for further clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Diosmetin exerts cardioprotective effect on myocardial ischaemia injury in neonatal rats by decreasing oxidative stress and myocardial apoptosis

Zhang³

et al. 2020

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor

Zeng

Chen

et al. 2020

Cell Cycle

View full text Add to dashboard Cite

Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis

Martinez¹,

Zoretic²,

Moreira

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Adult clinical trials have reported safety and the therapeutic potential of stem cells for cardiac disease. These observations have now translated to the pediatric arena. We conducted a meta-analysis to assess safety and efficacy of cell-based therapies in animal and human studies of pediatric heart disease. Methods and results A literature search was conducted to examine the effects of cell-based therapies on: (i) safety and (ii) cardiac function. In total, 18 pre-clinical and 13 human studies were included. Pre-clinical: right ventricular dysfunction was the most common animal model (80%). Cardiac-derived (28%) and umbilical cord blood (24%) cells were delivered intravenously (36%) or intramyocardially (35%). Mortality was similar between cell-based and control groups (OR 0.94; 95% CI 0.05, 17.41). Cell-based treatments preserved ejection fraction by 6.9% ( p < 0.01), while intramyocardial at a dose of 1–10 M cells/kg optimized ejection fraction. Clinical: single ventricle physiology was the most common cardiac disease ( n = 9). Cardiac tissue was a frequent cell source, dosed from 3.0 × 10 5 to 2.4 × 10 7 cells/kg. A decrease in adverse events occurred in the cell-based cohort (OR 0.17, p < 0.01). Administration of cell-based therapies improved ejection fraction (MD 4.84; 95% CI 1.62, 8.07; p < 0.01). Conclusions In this meta-analysis, cell-based therapies were safe and improved specific measures of cardiac function. Implications from this review may provide methodologic recommendations (source, dose, route, timing) for future clinical trials. Of note, many of the results described in this study pattern those seen in adult stem cell reviews and meta-analyses.

show abstract

Neonatal myocardial infarction: substantial improvement of cardiac function after autologous bone marrow-derived cell therapy

Cited by 3 publications

References 18 publications

RETRACTED: Diosmetin exerts cardioprotective effect on myocardial ischaemia injury in neonatal rats by decreasing oxidative stress and myocardial apoptosis

RETRACTED: Diosmetin exerts cardioprotective effect on myocardial ischaemia injury in neonatal rats by decreasing oxidative stress and myocardial apoptosis

Knockdown of miR-1275 protects against cardiomyocytes injury through promoting neuromedin U type 1 receptor

Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About